What changed: Glioma & glioblastoma

When this page itself was last checked or edited.

A milestone in how this cancer is treated.

Accelerated approval on a surrogate endpoint; the confirmatory requirement was still open 1.1 years later, when the FDA's table was read.

Recurrent H3 K27M-mutant diffuse midline glioma, age ≥1 (accelerated)

6 August 2025; first systemic therapy for the disease.

Regorafenib, the first arm, did not improve overall survival in newly diagnosed or recurrent glioblastoma; paxalisib and VAL-083 did not graduate; later arms continue.

A milestone in how this cancer is treated.

OS 13.

PFS 27.

A milestone in how this cancer is treated.

OS 28.

A milestone in how this cancer is treated.

Temozolomide alone gave shorter progression-free survival than radiotherapy-containing treatment in 1p/19q-codeleted glioma; the redesigned comparison of radiotherapy with temozolomide against radiotherapy with PCV is ongoing.

A milestone in how this cancer is treated.

OS 9.

6-month PFS 20% vs 16%; median OS 11.

CheckMate 548 (2022) and CheckMate 498 (2023) follow in newly diagnosed disease; all three negative.

Depatuxizumab mafodotin added to radiotherapy and temozolomide did not improve overall survival in EGFR-amplified glioblastoma; stopped for futility.

Bevacizumab added to radiotherapy and temozolomide did not improve event-free survival in newly diagnosed paediatric high-grade glioma.

Imaging agent for visualisation of malignant tissue during glioma surgery (suspected high-grade)

Adjuvant temozolomide: overall survival hazard ratio 0.

OS 9.

A milestone in how this cancer is treated.

OS 20.

Median progression-free survival 46 (radiotherapy) vs 39 months (temozolomide), no significant difference.

A milestone in how this cancer is treated.

Newly diagnosed glioblastoma with temozolomide (EF-14)

OS 20.

A milestone in how this cancer is treated.

Bevacizumab added to radiotherapy and temozolomide prolonged progression-free survival but not overall survival in newly diagnosed glioblastoma.

A milestone in how this cancer is treated.

Median overall survival 42.

1p/19q co-deleted: median overall survival 14.

Median overall survival 8.

PMA approval, recurrent glioblastoma

Recurrent glioblastoma (newly diagnosed 2015)

Recurrent glioblastoma (accelerated; full approval 2017)

Radiographic response without survival benefit.

Parsons/Vogelstein glioblastoma genome sequencing; reclassification follows.

Visualisation of malignant tissue during surgery for WHO grade III-IV glioma

NSCLC; later ovarian, cervical, RCC, glioblastoma, HCC

Newly diagnosed glioblastoma with radiotherapy

OS 14.

A milestone in how this cancer is treated.

Temodal; malignant glioma (recurrent 1999; newly diagnosed glioblastoma with radiotherapy 2005); 26 Jan 1999

A milestone in how this cancer is treated.

Recurrent glioblastoma as an adjunct to surgery (Gliadel Wafer); newly diagnosed high-grade glioma with surgery and radiation added 2003

Whole-brain then involved-field radiation becomes standard.

Histologic classification that lasted, in essence, until 2016.